Table 1 Summary of patients characteristics at treatment start.
RA | 3DC | ||
|---|---|---|---|
Number of patients | 25 | 20 | |
Males | 76% (19/25) | 65% (13/20) | |
Females | 24% (6/25) | 35% (7/20) | |
Age [years] (median and range) | 65.4 [37, 85] | 63.5 [46, 79] | |
Hystology | Adenoca | Adenoca | |
Stage T | T2 | 0% (0/25) | 15% (3/20) |
T3 | 84% (21/25) | 75% (15/20) | |
T4 | 16% (4/25) | 10% (2/20) | |
Stage N | N0 | 48% (12/25) | 40% (8/20) |
N1 | 44% (11/25) | 35% (7/20) | |
N2 | 4% (1/25) | 10% (2/20) | |
Nx | 4% (1/25) | 15% (3/20) | |
Stage M | M0 | 96% (24/25) | 95% (19/20) |
M1 | 4% (1/25) | 5% (1/20) | |
Grade G | G1 | 4% (1/25) | 10% 2/20) |
G2 | 84% (21/25) | 90% (18/20) | |
G3 | 12% (3/25) | 0% (0/20) | |
Location | Low | 48% (12/25) | 15% (3/20) |
Medium | 16% (4/25) | 45% (9/20) | |
High | 36% (9/25) | 40% (8/20) | |
Chemotherapy | Capecitabin | 92% (23/25) | 100% (20/20) |
No chemio | 8% (2/25) | 0% (0/20) | |
Surgery | Pre-op | 80% (20/25) | 90% (18/20) |
Post-op | 16% (4/25) | 10% (2/20) | |
Non-op | 4% (1/25) | 0% (0/20) | |
Radiation Dose Prescription | 44 Gy/22 fractions | 72% (18/25) | 80% (16/20) |
45 Gy/25 fractions | 20% (5/25) | 20% (4/20) | |
40 Gy/20 fractions | 8% (2/25) | 0% (0/20) | |
Radiation Boost | 50.4 Gy | 12% (3/25) | 25% (5/20) |
Dose Prescription | 54.0 Gy | 4% (1/25) | 0% (0/20) |